1972 年 92 巻 1 号 p. 11-18
The effect of bimetopyrol [2-methyl-4, 5-bis (p-methoxyphenyl) pyrrole], a novel anti-inflammatory drug, on adjuvant arthritis was compared with that of phenylbutazone, flufenamic acid, and indomethacin. 1) In the exploratory prophylactic experiment on adjuvant arthritis, all four drugs suppressed swelling in adjuvant-injected and non-injected feet in different degrees, where Bimetopyrol was several times more potent than phenylbutazone. Morbid anatomical evaluation of the animals, such as in body and organ weights and albumin-globulin ratio in serum, was also practically in agreement with that observed in foot swelling. 2) In order to obtain a more precise potency ratio between bimetopyrol and phenylbutazone, a single self-contained experiment was carried out, specified by the use of wellestablished arthritic animals, the injection of adjuvant into the tail rather than the foot and the use of a single preparation for each drug throughout the experiment. By 6-point bioassay, therapeutic potency of bimetopyrol was revealed to be 5.2 to 6.9 times more potent than phenylbutazone. 3) Possible clinical application of bimetopyrol being taken into account, medication of this drug was carried out with arthritic rats after a prolonged pretreatment with dexamethasone. The rebound of foot swelling occurring after withdrawal of corticosteroid was suppressed completely by replacement with bimetopyrol. Furthermore, thymic atrophy caused by corticosteroid was favorably recovered after this type of substitution of drugs.